GUARNERI, Valentina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.877
EU - Europa 5.713
AS - Asia 1.678
AF - Africa 28
SA - Sud America 19
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 9
Totale 18.335
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.839
GB - Regno Unito 1.478
IT - Italia 1.456
IE - Irlanda 840
SE - Svezia 601
CN - Cina 595
DE - Germania 416
HK - Hong Kong 389
UA - Ucraina 365
SG - Singapore 218
TR - Turchia 200
FI - Finlandia 186
BG - Bulgaria 137
IN - India 90
FR - Francia 70
ID - Indonesia 48
VN - Vietnam 47
CA - Canada 33
BE - Belgio 23
LT - Lituania 23
RU - Federazione Russa 19
IR - Iran 18
KR - Corea 16
ES - Italia 15
MY - Malesia 14
NL - Olanda 12
TW - Taiwan 11
CH - Svizzera 10
GR - Grecia 10
JP - Giappone 10
CZ - Repubblica Ceca 9
AU - Australia 8
EG - Egitto 8
BR - Brasile 7
ET - Etiopia 7
EU - Europa 7
CL - Cile 6
HU - Ungheria 6
MX - Messico 5
RO - Romania 5
AL - Albania 4
DK - Danimarca 4
IQ - Iraq 4
KE - Kenya 4
MA - Marocco 4
MK - Macedonia 4
PL - Polonia 4
SI - Slovenia 4
AP - ???statistics.table.value.countryCode.AP??? 3
AT - Austria 3
CO - Colombia 3
BD - Bangladesh 2
BH - Bahrain 2
BO - Bolivia 2
CY - Cipro 2
LY - Libia 2
NO - Norvegia 2
PK - Pakistan 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BY - Bielorussia 1
EC - Ecuador 1
LB - Libano 1
LI - Liechtenstein 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
MZ - Mozambico 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
TH - Thailandia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 18.335
Salva come PNG Salva come JPEG
Città #
Fairfield 1.456
Southend 1.136
Woodbridge 1.092
Chandler 916
Houston 868
Dublin 840
Ashburn 806
Jacksonville 730
Dearborn 621
Ann Arbor 581
Seattle 537
Wilmington 497
Cambridge 483
Nyköping 434
Hong Kong 382
Beijing 228
Modena 201
San Diego 160
Princeton 156
Singapore 148
Sofia 137
New York 135
Eugene 131
Izmir 124
Milan 109
Helsinki 83
Rome 83
Falls Church 57
Des Moines 56
Shanghai 56
Jakarta 48
London 48
Dong Ket 41
Bologna 38
Norwalk 38
Bremen 37
Redwood City 35
Fremont 30
Boardman 29
Turin 29
Naples 26
Nanjing 23
San Mateo 23
Brussels 20
Hefei 20
Bari 19
Palermo 19
Catania 18
Guangzhou 17
Genoa 16
Los Angeles 16
Padova 16
Vicenza 15
Florence 14
Ottawa 14
Kunming 13
Mumbai 13
Kilburn 12
Toronto 12
Lansdale 11
Monmouth Junction 11
Wuhan 11
Chiswick 10
Phoenix 10
Pisa 10
Verona 10
Chicago 9
Fulham 9
Jinan 9
Parma 9
Augusta 8
Bangalore 8
Dallas 8
Nanchang 8
Perugia 8
Taipei 8
Ardabil 7
Athens 7
Frankfurt am Main 7
Hounslow 7
Prescot 7
Shenyang 7
Stockholm 7
Ancona 6
Berlin 6
Brescia 6
Brno 6
Cagliari 6
Ferrara 6
Fuzhou 6
Gelsenkirchen 6
Hanoi 6
Islington 6
Leawood 6
Madrid 6
Monte Porzio 6
Mountain View 6
Munich 6
Reggio Emilia 6
Torrile 6
Totale 14.250
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 612
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 296
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 280
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 242
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 240
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 239
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 219
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 209
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 208
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 208
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 200
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 196
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 195
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 193
Immune characterization of breast cancer metastases: prognostic implications. 193
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 191
Achievements and unmet needs in the management of advanced ovarian cancer 185
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 183
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 183
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 181
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 181
Timing for starting second line therapy in recurrent ovarian cancer. 179
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 173
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 171
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 171
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 170
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 170
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 169
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 166
Trastuzumab containing regimens for early breast cancer. 164
Trastuzumab-containing regimens for metastatic breast cancer 162
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 162
Downregulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 Might Correlate with Poor Disease-Free and Overall Survival in Inflammatory Breast Cancer 158
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 158
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 158
Detection of microparticles from human red blood cells by multiparametric flow cytometry 154
Triple-negative breast cancer: current management and future options. 154
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 152
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 150
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 149
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. 146
Biomarkers predicting clinical benefit: fact or fiction? 144
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients 144
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 142
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 141
Bevacizumab treatment for advanced breast cancer. 140
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 138
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" 136
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 136
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 135
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 134
Controversies of chemotherapy for the treatment of metastatic breast cancer. 134
The Next Generation of Biologic Agents: Therapeutic Role in Relation to Existing Therapies in Metastatic Breast Cancer 133
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 133
The curability of breast cancer and the treatment of advanced disease 131
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer 129
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study 129
Primary Systemic Therapy in operable breast cancer: clinical data and biological fall-out 128
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer 128
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 128
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer 127
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 127
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 126
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support 125
In response to Jackson letter to the editor regarding "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens" 125
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 125
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 125
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 125
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 124
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial. 123
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 122
Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC). 121
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study 121
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 121
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study 119
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001 119
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY 118
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY. 118
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma 118
Tumori ginecologici 116
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability 114
Progress in the treatment of Early and Advanced Breast Cancer 114
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 113
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden 113
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens 113
Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial. 111
Biomarker expression and survival after primary chemotherapy for breast cancer. 110
Bone metastases- Pharmacological treatment 109
Pazopanib-Induced Heart Failure In A Metastastic Sarcoma Patient: Between Reversible Side Effect and Efficacy 109
Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience 109
Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy 109
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors 108
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2þ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. 108
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 107
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 107
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates 105
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 105
Clinical utility of measuring circulating tumor cells in metastatic breast cancer 104
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 104
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 102
Totale 15.252
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.439
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.439
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.092 0 0 151 237 428 564 615 313 310 111 219 144
2020/20212.950 293 163 249 214 297 224 251 356 161 345 240 157
2021/20222.363 61 280 288 108 64 135 149 119 278 202 394 285
2022/20233.462 331 307 174 248 282 375 52 248 1.156 48 137 104
2023/20242.185 98 131 120 134 324 172 169 437 75 115 161 249
2024/2025302 185 117 0 0 0 0 0 0 0 0 0 0
Totale 18.553